
AVEO Pharmaceuticals AVEO
Quarterly report 2022-Q3
added 05-16-2026
AVEO Pharmaceuticals Long Term Debt Current 2011-2026 | AVEO
Annual Long Term Debt Current AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 K | 369 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 369 K | 11 K | 190 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 7.42 | 5.55 % | $ 203 M | ||
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.71 | 5.9 % | $ 200 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 92.36 | 0.24 % | $ 22.3 B | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Compugen Ltd.
CGEN
|
521 K | $ 2.68 | -4.29 % | $ 250 M | ||
|
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
235 K | $ 0.68 | -5.59 % | $ 31.1 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | -0.16 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 31.34 | -3.84 % | $ 843 M | ||
|
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 22.15 | 2.59 % | $ 287 M | ||
|
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | ||
|
IMV
IMV
|
320 K | - | - | $ 13.1 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.02 | 0.44 % | $ 5.45 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.66 M | - | - | $ 384 M | ||
|
Heron Therapeutics
HRTX
|
3.04 M | $ 0.86 | -0.05 % | $ 143 M | ||
|
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
2.05 M | $ 14.8 | -0.54 % | $ 212 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
InflaRx N.V.
IFRX
|
257 K | $ 2.73 | 4.62 % | $ 184 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.55 | 4.26 % | $ 5.84 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
1.4 M | - | -0.23 % | $ 916 M |